MedTrace Logo

Mechanism of Hypersensitivity Reactions to Iron Nanomedicines

NCT03508466 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2020-02-25

No results posted yet for this study

Summary

Iron deficiency is common and when oral treatment is not sufficient intravenous application is indicated. Hypersensitivity to intravenous iron nanomedicines is rare but does occur and little is known about the underlying mechanism but complement activation has been suggested.

This is a purely exploratory study as it is not yet known whether in vitro complement activation can be stimulated by titration with iron preparations. These data will provide first empirical evidence of whether and to what extent complement activation occurs in this population.

Conditions

  • Iron-deficiency

Interventions

BEHAVIORAL

hypersensitivity reaction

Previous hypersensitivity reaction

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Esther H Steveling-Klein, Dr., MD · University Hospital, Basel, Switzerland

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03508466 on ClinicalTrials.gov